10 Overlooked Growth Stocks to Buy Now
On April 14, Tom Lee, Fundstrat's Head of Research, joined CNBC's 'Power Lunch' to discuss his outlook on equities.
Ultragenyx Pharmaceutical Inc. (RARE)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 2,772,692 | $63,771,916 | 0.37% | |
| 2. | Citadel Investment Group Ken Griffin | 2,326,125 | $53,500,875 | +603% | 0.01% |
| 3. | Suvretta Capital Management Aaron Cowen | 2,019,000 | $46,437,000 | 0.95% | |
| 4. | AQR Capital Management Cliff Asness | 1,360,497 | $31,291,431 | +83% | 0.02% |
| 5. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 1,267,241 | $29,146,543 | +2% | 1.49% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $43.63 | 5,000 | $218,150.00 | 472,479 | 2019-09-11 | Filing | |
| $52.96 | 1,647 | $87,225.12 | 2,559,741 | 2017-08-28 | Filing | |
| $52.40 | 5,853 | $306,697.20 | 2,558,094 | 2017-08-28 | Filing | |
| $21.00 | 175,000 | $3,675,000.00 | 3,260,240 | 2014-01-31 | Filing | |
| $21.00 | 4,500 | $94,500.00 | 84,255 | 2014-01-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.97 | 4,683 | $98,202.51 | 80,351 | 2026-04-01 | Filing | |
| $22.80 | 10,029 | $228,661.20 | 110,026 | 2026-03-02 | Filing | |
| $22.80 | 10,539 | $240,289.20 | 89,515 | 2026-03-02 | Filing | |
| $22.80 | 54,404 | $1,240,411.20 | 658,994 | 2026-03-02 | Filing | |
| $22.80 | 8,135 | $185,478.00 | 76,346 | 2026-03-02 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,257,671 | $47,298,207 | 0.07% | |
| 2. | 603,571 | $11,671,195 | 0.01% | |
| 3. | 102,710 | $2,151,775 | 0.03% | |
| 4. | 86,917 | $1,820,911 | 0.01% | |
| 5. | 44,908 | $940,823 | 0.01% |
News See All
7 Best Small-Cap Healthcare Stocks to Buy According to Hedge Funds
In this article, we will look at the best small-cap healthcare stocks to buy according to hedge funds.
Ultragenyx Pharmaceutical Inc. (RARE): A Bull Case Theory
We came across a bullish thesis on Ultragenyx Pharmaceutical Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we will summarize the bulls’ thesis on RARE.
Strong Rare Disease Pipeline Drives Favorable Sentiment for Ultragenyx (RARE)
On February 3, the price target on Ultragenyx Pharmaceutical (NASDAQ:RARE) was set to $60 by H.C. Wainwright analyst Ram Selvaraju, who maintained a Buy rating on the stock.
17 Biotechnology Stocks with More Than 50% Upside
2025 was a year characterized by both challenges and opportunities for the biotechnology sector.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2025 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2025 Earnings Call Transcript February 12, 2026Ultragenyx Pharmaceutical Inc. misses on earnings expectations.
Ultragenyx (RARE) Announces Positive Long-Term Clinical Data for UX111 Gene Therapy in Sanfilippo Syndrome Type A
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the most promising low-cost stocks to buy now.
11 Most Promising Low-Cost Stocks to Buy Now
On February 7, Richard Bernstein, CEO of Richard Bernstein Advisors, joined 'The Exchange' on CNBC to discuss the state of equity markets, assessing which stocks are growing fast and trading cheaply.
Ultragenyx Pharmaceutical (RARE) Resubmits Biologics License Application for Gene Therapy Treatment
On January 30, Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE) resubmitted its Biologics License Application (BLA) to the U.S.
13 Best Revenue Growth Stocks to Buy Right Now
Speaking to CNBC on January 13, Ari Wald, Head of Technical Analysis at Oppenheimer, said U.S.